Régis Angonin
University of Franche-Comté
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Régis Angonin.
British Journal of Haematology | 2005
Marie-Blanche Valnet-Rabier; Bruno Challier; Sylvie Thiebault; Régis Angonin; Geneviève Margueritte; Christiane Mougin; Bernadette Kantelip; Eric Deconinck; Jean-Yves Cahn; Thierry Fest
The World Health Organization Classification of Lymphoid Neoplasms identifies Burkitts lymphoma/leukaemia (BL) as a single entity, characterized by unique clinical and genetic features that require specific high intensity chemotherapy regimens. Although remarkable successes in the treatment of the disease have been observed, when compared with paediatric patients, adults are less likely to reach stable complete remission. We investigated 32 BL cases, composed in equal part by adults and children that were treated with the French LMB regimen, for factors that may be implicated in chemoresistance. Immunohistochemical detection of procaspase‐8, caspase‐3a, survivin, p53, CD95, c‐Flip and Phospho‐RelA (Ser536) was investigated on paraffin‐embedded tissues. The expression of c‐Flip was found highly related to a poor prognosis, mostly characterized by adults with a chemoresistant disease, resulting in a high death rate within the first year of diagnosis. The 2‐year overall survival with c‐Flip expression was 24% compared with 93% in the absence of this marker (P = 0·04). All c‐Flip‐positive BL cases presented a nuclear Phospho‐RelA (Ser536) localization, suggesting the presence of an active nuclear factor (NF)‐κB transcription pathway. These findings show that c‐Flip could be a reliable prognostic factor in BL, suggesting new therapeutic approaches that target the NF‐κB pathway.
Transplantation | 2006
Sylvain Perruche; Aliette Marandin; F. Kleinclauss; Régis Angonin; Stéphanie Fresnay; Marie Hélène Baron; Pierre Tiberghien; Philippe Saas
Background. Use of a reduced-intensity conditioning regimen before an allogeneic hematopoietic cell transplantation is frequently associated with an early state of mixed hematopoietic chimerism. Such a coexistence of both host and donor hematopoietic cells may influence posttransplant alloreactivity and may affect the occurrence and severity of acute and chronic graft-versus-host disease (GVHD) as well as the intensity of the graft-versus-leukemia effect. Here we evaluated the relation between chimerism state after reduced-intensity conditioning transplantation (RICT), autoantibody production, and chronic GVHD (cGVHD)-related pathology. Methods. Chimerism state, circulating anticardiolipin, and antidouble stranded DNA autoantibody (Ab) titers as well as occurrence of cGVHD-like lesions were investigated in a murine RICT model. Results. We observed a novel association between mixed chimerism state, high levels of pathogenic IgG autoantibodies, and subsequent development of cGVHD-like lesions. Furthermore, we found that the persistence of host B cells, but not dendritic cell origin or subset, was a factor associated with the appearance of cGVHD-like lesions. The implication of host B cells was confirmed by a host origin of autoantibodies. Conclusion. Recipient B cell persistence may contribute to the frequency and/or severity of cGVHD after RICT.
Cornea | 2002
Marie-Paule Algros; Régis Angonin; B. Delbosc; Jean-Yves Cahn; Bernadette Kantelip
Purpose. To report a case of posttransplant lymphoproliferative disorder (PTLD) in a patient receiving oral cyclosporine (CS) for immunosuppression in a high-risk keratoplasty. Methods. A systemic CS therapy was given to prevent graft rejection of a keratoplasty. Risk rejection was high in regard to a previous graft rejection and persistence of a corneal vascularization. One year after the keratoplasty, the patient developed a gastric Epstein-Barr virus (EBV)-induced B cell lymphoma. The outcome was favorable after chemotherapy. Conclusions. This unique case of lymphoma (PTLD) in the course of corneal graft management questions the indications and the follow-up of patients with CS therapy and raises the issue of topical CS treatment.
Transplantation | 1996
Herve; Mabed M; Laithier; Pavy Jj; Régis Angonin; Emmanuel Contassot; Certoux Jm; Jean-Yves Cahn; Patrick Herve; Pierre Tiberghien
The administration of IL-1, a potent radioprotective cytokine, before allogeneic BMT is associated with an early transient increase of circulating granulocytes, successful engraftment, and accelerated multilineage hematopoietic recovery. We have examined the effects of IL-1 alpha pretreatment on the engraftment of an allogeneic BMT unable to sustain survival by itself after a lethal irradiation: (1) transplantation of a limited amount of marrow cells and (2) transplantation several days after irradiation. IL-1 was unable to allow the engraftment of an early quantitatively inadequate BMT. However, delayed BMT with limited amounts of marrow cells was associated with engraftment in IL-1 pretreated recipients. Engraftment of a late (day 12) BMT in these IL-1-pretreated mice was comparable to the engraftment of a similar day 12 allogeneic BMT in non-IL-1-pretreated mice rescued from the lethal irradiation by an early (day 1) syngeneic graft. These findings demonstrate that IL-1 pretreatment can result in a dissociation between BMT-induced survival and engraftment and suggest that the favorable effects of IL-1 pretreatment in an allogeneic BMT setting are mainly mediated through a transient enhancement of endogenous hematopoiesis and not through a direct effect on the allogeneic stem cells present in the marrow graft.
Transplantation | 2007
Isabelle Mermet; F. Kleinclauss; Aliette Marandin; Jean Sébastien Guérrini; Régis Angonin; Pierre Tiberghien; Philippe Saas; F. Aubin
Although previous studies have demonstrated the efficient modulatory effects of ultraviolet radiation B (UVB) on cutaneous graft-versus-host disease (GVHD), most animal research on GVHD has been performed in murine models of acute GVHD. Here, we studied the preventive effect of UVB radiation on the occurrence of chronic sclerodermatous (Scl) GVHD in a murine model. Scl GVHD was induced by transplanting lethally irradiated BALB/c mice with B10.D2 bone marrow and spleen cells. Recipient mice were exposed to UVB before or after bone marrow and spleen cell infusion. Histological and clinical evaluation of GVHD was performed, in association with the characterization of epidermal Langerhans cells. UVB irradiation of recipients after, and more remarkably before, transplantation induced a decrease of Scl GVHD severity associated with epidermal Langerhans cells depletion. We conclude that UVB irradiation of recipient before or after transplantation has a preventive effect on cutaneous Scl GVHD and may represent an effective strategy for prevention of Scl GVHD.
Annals of Hematology | 2006
Mohamed Mabed; Christian Coffe; Evelyne Racadot; Régis Angonin; Jean-Jaques Pavey; Pierre Tiberghien; Patrick Herve
The combination of 8-methoxypsoralen (8-MOP) and long wave ultraviolet radiation (UV-A) has immunomodulatory effects and might abolish both graft-vs-host and host-vs-graft reactions after allogeneic hematopoietic stem cell transplantation. In the present study, we have confirmed the sensitivity of T lymphocytes to 8-MOP treatment plus UV-A exposure as evidenced by the abrogation of the alloreactivity in mixed lymphocyte cultures as well as the inhibition of the response to phytohemagglutinin A. However, the clonogenic capacity of the bone marrow hematopoietic progenitors was inhibited with UV-A doses lower than the doses needed to inhibit T-lymphocytes alloreactivity. Moreover, long-term bone marrow cultures showed that 8-MOP plus UV-A treatment had detrimental effects on the more immature bone marrow stem cells. These data were confirmed when murine bone marrow graft was treated with 8-MOP, exposed to UV-A, then transplanted into semiallogeneic recipient mice. The treated cells could not maintain their clonogenic capacity in vivo resulting in death of all animals. Taken together, these data show that ex vivo 8-MOP plus UV-A treatment of the marrow graft cannot be used to prevent post-bone marrow transplantation alloreactivity.
Blood | 2003
Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Hervé Tilly; Christian Bastard; Régis Angonin; Eric Deconinck; Frédéric Charlotte; Véronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-François Emile; Béatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Blood | 2001
Pierre Tiberghien; Christophe Ferrand; Bruno Lioure; Noel Milpied; Régis Angonin; Eric Deconinck; Jean-Marie Certoux; Eric Robinet; Philippe Saas; Bruno Petracca; Chris Juttner; Craig W. Reynolds; Dan L. Longo; Patrick Herve; Jean-Yves Cahn
Blood | 2001
Marcelo de Carvalho Bittencourt; Sylvain Perruche; Emmanuel Contassot; Stéphanie Fresnay; Marie-Hélène Baron; Régis Angonin; F. Aubin; Patrick Herve; Pierre Tiberghien; Philippe Saas
Blood | 1998
Franck Carbonnel; Laurence Grollet-Bioul; Jean Claude Brouet; Marie Françoise Teilhac; Jacques Cosnes; Régis Angonin; Marie Deschaseaux; François-Patrick Châtelet; Jean Pierre Gendre; François Sigaux